COMPANY RESEARCHExtends molecular building-block products into medicinal chemistry, process development, and GMP API/drug-product manufacturing, including continuous-flow technology.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Amounts retain their original currency and units. Consolidated group revenue is not standalone CRO/CDMO service revenue. Year-to-date periods are not standalone quarters.
| Period | Currency / basis | Revenue | Net profit | Operating cash flow | Report |
|---|---|---|---|---|---|
| FY2025 2025-12-31 | CNY PRC Accounting Standards / consolidated | 1,974,477,816.91 | 183,735,514.39 Net income attributable to shareholders of the listed company | 667,360,829.32 | Original ↗ |
| 2026Q3 (YTD) 2026-09-30 | CNY PRC Accounting Standards / consolidated | 1,634,163,797.33 | 151,216,132.02 Net income attributable to shareholders of the listed company | 251,371,404.29 | Original ↗ |
Disease tags match recorded text mentions and require program-level verification.
Extends molecular building-block products into medicinal chemistry, process development, and GMP API/drug-product manufacturing, including continuous-flow technology.
Listed as SZSE 300725; original 2025 annual and 2026Q3 (YTD) reports reviewed.
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| Building blocks / medicinal chemistry / CMC-CDMO | Not applicable (services/platform) · Drug research and manufacturing services for clients | Services / platform | Not applicable: service capabilities are not clinical drug candidates; E4 does not rate service quality. |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
PharmaBlock Sciences reported consolidated revenue of RMB1.634 billion, up 15.16%, and attributable net income of RMB151.2 million for the nine months ended September 30, 2026. Attributable net income rose 33.36%, while net cash from operations declined 53.75% over the same period. The quarterly filing is unaudited and covers the year-to-date period.
Fresenius signed an exclusive development agreement with WuXi Biologics providing access to up to 37 biosimilar candidates over the next decade. Initial work is expected to focus on polatuzumab vedotin and teprotumumab biosimilars. Fresenius retains selection flexibility and commercialization economics; the candidate count is an option-based opportunity, not 37 approved products.
Biocytogen reported consolidated revenue of RMB1.403 billion, up 49.09%, and attributable net income of RMB312.4 million for the nine months ended September 30, 2026. Attributable net income increased 173.77%. The group combines animal models, research services, and antibody licensing activities. The quarterly filing is unaudited and covers the year-to-date period.
Haoyuan Chemexpress reported consolidated revenue of RMB2.646 billion, up 28.52%, and attributable net income of RMB308.8 million for the nine months ended September 30, 2026. Attributable net income rose 30.49%. Consolidated revenue combines multiple businesses rather than isolating CDMO service revenue. The quarterly filing is unaudited and covers the year-to-date period.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.
